ZEALAND PHARMA A/S: Financial statements 2014
CVR: 20045078
Source: annual report 2014, Danish Business Authority
01/01/2014 – 31/12/2014
ZEALAND PHARMA A/S (CVR 20045078) has filed annual accounts for 2014. In 2014, the company reported revenue of DKK 153,773,000 and a net result of DKK -64,990,000. The profit margin was -42.3%. Equity in the 2014 report amounted to DKK 252,828,000. The solvency ratio was 42.4%.
- Revenue
- DKK 153,773,000
- Gross Profit
- DKK 139,997,000
- Profit/Loss
- DKK -64,990,000
- Equity
- DKK 252,828,000
- Total Assets
- DKK 596,756,000
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2014
As of December 31, 2014, Søren Vitfell Keller has left the board of directors of ZEALAND PHARMA A/S.
As of December 31, 2014, Maria Juul Kolding has left the board of directors of ZEALAND PHARMA A/S.
ZEALAND PHARMA A/S has published its annual report for 2013.
As of April 29, 2014, DELOITTE STATSAUTORISERET REVISIONSPARTNERSELSKAB has been appointed auditor of ZEALAND PHARMA A/S.
As of April 29, 2014, PRICEWATERHOUSECOOPERS STATSAUTORISERET REVISIONSPARTNERSELSKAB has stepped down as auditor of ZEALAND PHARMA A/S.
As of April 29, 2014, Søren Vitfell Keller has joined the board of directors of ZEALAND PHARMA A/S.
As of April 29, 2014, Hanne Heidenheim Bak has joined the board of directors of ZEALAND PHARMA A/S.
As of April 29, 2014, Jens Peter Stenvang has joined the board of directors of ZEALAND PHARMA A/S.
As of April 29, 2014, Maria Juul Kolding has joined the board of directors of ZEALAND PHARMA A/S.
As of April 29, 2014, Jutta Grevinde af Rosenborg has left the board of directors of ZEALAND PHARMA A/S.
About ZEALAND PHARMA A/S
ZEALAND PHARMA A/S is a Danish company of the type Aktieselskab based in Søborg, founded in 1997. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company was previously named ZEALAND PHARMACEUTICALS A/S and PEPTIDE PROBE TECHNOLOGIES ApS. The management consists of Adam Sinding Steensberg and Henriette Wennicke. The board consists of Alf Gunnar Martin Nicklasson (chair), Kirsten Aarup Drejer, Adam Krisko Nygaard and Anneline Nansen. The company's owners include ZEALAND PHARMA A/S, Van Herk Investments B.V. and Van Herk Management Services B.V.. The company has 575 employees (2026). In 2025, the company reported revenue of DKK 9,214,860,000 and a net result of DKK 6,455,008,000 compared with DKK -1,078,828,000 the year before. Equity in the 2025 report amounted to DKK 14,830,613,000.
